Published in Int J Oncol on February 01, 2005
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Analysis of tissue-specific differentially methylated regions (TDMs) in humans. Genomics (2006) 1.60
Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene (2006) 1.46
Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett (2012) 1.36
Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure. Environ Health Perspect (2006) 1.30
Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia (2010) 0.94
Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma. J Cell Mol Med (2010) 0.94
Gene expression profiling of naïve sheep genetically resistant and susceptible to gastrointestinal nematodes. BMC Genomics (2006) 0.90
Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis (2008) 0.87
Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma. Oncotarget (2016) 0.81
Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules. Thyroid Res (2011) 0.78
Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling. Biomark Insights (2007) 0.78
Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions. Cancer Sci (2015) 0.77
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 25.57
Global cancer statistics in the year 2000. Lancet Oncol (2001) 11.11
Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol (2003) 2.86
Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol (2002) 2.08
Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol (1999) 2.07
Developmental competence of the gut endoderm: genetic potentiation by GATA and HNF3/fork head proteins. Dev Biol (1999) 1.95
Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res (2003) 1.90
Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.74
Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci U S A (2000) 1.66
Trefoil peptides: from structure to function. Cell Mol Life Sci (1997) 1.61
Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene (2001) 1.50
The mouse one P-domain (pS2) and two P-domain (mSP) genes exhibit distinct patterns of expression. J Cell Biol (1993) 1.41
Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest (1997) 1.39
Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J Pathol (1997) 1.39
Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene (2004) 1.33
Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol (2000) 1.27
Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol (1997) 1.22
T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene. EMBO J (1989) 1.18
Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol (2002) 1.13
Global methylation screening in the Arabidopsis thaliana and Mus musculus genome: applications of virtual image restriction landmark genomic scanning (Vi-RLGS). Nucleic Acids Res (2003) 1.10
Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res (2002) 1.10
Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J (2001) 1.06
Trefoil factor family (TFF) peptides and cancer progression. Peptides (2004) 1.01
Two genes abrogate the inhibition of murine hepatocarcinogenesis by ovarian hormones. Proc Natl Acad Sci U S A (1996) 1.01
Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol (2002) 0.97
Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors. Am J Surg Pathol (1998) 0.95
Localization of TFF3, a new mucus-associated peptide of the human respiratory tract. Am J Respir Crit Care Med (1999) 0.94
Mouse Trefoil factor genes: genomic organization, sequences and methylation analyses. Gene (2001) 0.87
A novel mitochondrial carnitine-acylcarnitine translocase induced by partial hepatectomy and fasting. J Biol Chem (2003) 0.87
Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J Cell Biochem (1997) 0.85
Trefoil factor family domain peptides. Virchows Arch (1997) 0.85
Characterization of the mouse TFF1 (pS2) gene promoter region. Biol Pharm Bull (2001) 0.83
Transcriptional control of TFF3 (intestinal trefoil factor) via promoter binding sites for the nuclear factor kappaB and C/EBPbeta. Peptides (2004) 0.82
Coordinate late expression of trefoil peptide genes (pS2/TFF1 and ITF/TFF3) in human breast, colon, and gastric tumor cells exposed to X-rays. Mol Cancer Ther (2002) 0.79
Expression of intestinal trefoil factor mRNA is downregulated during progression of colorectal carcinomas. J Clin Pathol (1997) 0.79
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression. Proc Natl Acad Sci U S A (2005) 4.59
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med (2002) 4.25
Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13
The nature and identification of quantitative trait loci: a community's view. Nat Rev Genet (2003) 3.96
One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res (2004) 2.34
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med (2008) 2.27
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun (2002) 2.13
Regeneration and function of hemiliver graft: right versus left. Surgery (2006) 2.12
Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections. World J Surg (2004) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg (2003) 2.01
Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg (2003) 2.00
Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res (2009) 1.96
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg (2009) 1.87
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene (2005) 1.86
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg (2007) 1.82
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol (2010) 1.79
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol (2006) 1.72
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst (2008) 1.71
Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors of the antrum in mice. Gastroenterology (2011) 1.67
Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery (2003) 1.67
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis (2007) 1.60
Analysis of tissue-specific differentially methylated regions (TDMs) in humans. Genomics (2006) 1.60
Refinement of venous reconstruction using cryopreserved veins in right liver grafts. Liver Transpl (2004) 1.59
A novel gene silencer, pyrrole-imidazole polyamide targeting human lectin-like oxidized low-density lipoprotein receptor-1 gene improves endothelial cell function. J Hypertens (2009) 1.58
One orifice vein reconstruction in left liver plus caudate lobe grafts. Transplantation (2007) 1.57
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Clinical significance of extrahepatic bile duct resection for advanced gallbladder cancer. J Surg Oncol (2006) 1.56
Genome-wide survey reveals dynamic widespread tissue-specific changes in DNA methylation during development. BMC Genomics (2011) 1.56
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg (2005) 1.56
Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer (2003) 1.54
Intestinal tumor progression is associated with altered function of KLF5. J Biol Chem (2004) 1.53
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol (2005) 1.52
Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer (2005) 1.52
Portal vein complications after adult-to-adult living donor liver transplantation. Transpl Int (2008) 1.51
Systematic grading of morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.51
Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol (2003) 1.50
Transfusion criteria for fresh frozen plasma in liver resection: a 3 + 3 cohort expansion study. Arch Surg (2011) 1.50
Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg (2002) 1.49
Effects of highly purified eicosapentaenoic acid on erythrocyte fatty acid composition and leukocyte and colonic mucosa leukotriene B4 production in children with ulcerative colitis. J Pediatr Gastroenterol Nutr (2003) 1.48
Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma. J Gastroenterol (2004) 1.48
Applicability of enhanced recovery program for advanced liver surgery. World J Surg (2014) 1.48
Delay to formalin fixation effect on breast biomarkers. Mod Pathol (2009) 1.46
Ultrasonically assisted retrohepatic dissection for a liver hanging maneuver. Ann Surg (2005) 1.46
Hepatic arterial anatomy for right liver procurement from living donors. Liver Transpl (2004) 1.44
Evaluation of hepatic venous congestion: proposed indication criteria for hepatic vein reconstruction. Ann Surg (2002) 1.43
Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer (2005) 1.42
Tissue specific differentially methylated regions (TDMR): Changes in DNA methylation during development. Genomics (2008) 1.42
Two-stage pancreatojejunostomy in pancreaticoduodenectomy: a retrospective analysis of short-term results. Am J Surg (2008) 1.41
Bile duct preserving surgery for hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg (2015) 1.41
Could we or should we replace the conventional nomenclature of liver resections? Ann Surg (2013) 1.40
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol (2006) 1.39
Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg (2004) 1.37
Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol (2009) 1.35
Magnetic resonance findings of bile duct adenoma with calcification. Radiat Med (2006) 1.35
Usefulness of LigaSure for liver resection: analysis by randomized clinical trial. Am J Surg (2006) 1.35
Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery (2005) 1.32
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg (2008) 1.30
Current surgical treatment for bile duct cancer. World J Gastroenterol (2007) 1.30
Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol (2005) 1.29
Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery (2009) 1.29
Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene (2003) 1.28
Current status of primary malignant melanoma of the esophagus: clinical features, pathology, management and prognosis. J Gastroenterol (2011) 1.26
Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg (2014) 1.25
Report of the 16th follow-up survey of primary liver cancer. Hepatol Res (2005) 1.25
"Radical but conservative" is the main goal for ultrasonography-guided liver resection: prospective validation of this approach. J Am Coll Surg (2005) 1.25
Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol (2004) 1.23
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res (2015) 1.23
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res (2010) 1.22
Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg (2003) 1.21